LUND, SWEDEN--(Marketwire - August 11, 2010) -
· Laquinimod - Phase III trials proceeding as planned
· TASQ - final Phase II data presented at ASCO. Phase III preparations proceeding on schedule
· ANYARA - article published in Journal of Immunotherapy
· 57-57 - exploratory clinical trial under way. Development for treatment of orphan drug indication (systemic sclerosis/scleroderma) initiated
· ISI - project continuing according to plan
· RhuDex™ - preclinical studies completed during the year
· Net sales of SEK 6.1 M (5.2)
· Operating loss of SEK 102.4 M (loss: 118.5)
· Loss after tax SEK 108.3 M (loss: 118.6)
· Loss per share for the period amounted to SEK 1.67 (loss: 2.22)
· The company received approximately SEK 149 M from a directed share issue, cash and cash equivalents at the end of the period amounted to SEK 235 M
For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95 Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46-19 11 54 Hans Kolam CFO Tel: +46 (0)46-19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) PO Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
[HUG#1436937]
Active Biotech AB Interim report January - June 2010: http://hugin.info/1002/R/1436937/381820.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Active Biotech via Thomson Reuters ONE
